Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS

Despite extensive efforts, oncogenic KRAS remains resistant to targeted therapy. Combined downstream RAL-TBK1 and MEK inhibition induces only transient lung tumor shrinkage in KRAS-driven genetically engineered mouse models (GEMMs). Using the sensitive KRAS;LKB1 (KL) mutant background, we identify Y...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Kitajima, Shunsuke, Asahina, Hajime, Chen, Ting, Guo, Sujuan, Quiceno, Laura Gutierrez, Cavanaugh, Jillian D., Merlino, Ashley A., Tange, Shoichiro, Terai, Hideki, Kim, Jong Wook, Wang, Xiaoen, Zhou, Shan, Xu, Man, Wang, Stephen, Zhu, Zehua, Thai, Tran C., Takahashi, Chiaki, Wang, Yujin, Neve, Richard, Stinson, Susanna, Tamayo, Pablo, Watanabe, Hideo, Kirschmeier, Paul T., Wong, Kwok-Kin, Barbie, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6422029/
https://ncbi.nlm.nih.gov/pubmed/30205046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2018.08.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados